LIST OF FIGURES

LIST OF FIGURES

FIGURE	TITLE	PAGE NO.
	CHAPTER-1	
1.1	Global projections for the diabetes epidemic	2
1.2	Insulin signaling pathway	8
1.3	Molecular mechanism of Insulin resistance	12
1.4	Intertissue relationship in TIIDM	13
1.5	FFA and Lipoprotein metabolism in peripheral tissues	16
1.6	Remodeling in adipose tissue in different physiological conditions	19
1.7	Stages of 3T3-L1 pre-adipocyte differentiation	20
1.8	Structure of human PARP-1 protein	22
1.9	TGF-β signalling	25
1.10	Model for the mechanism of metformin	30
	CHAPTER-3	
3.1a	Chemical structure of SM	66
3.1b	Overlay of UV absorption spectrum of SM isolated in lab and reference standard.	66
3.1c	TLC profile observed under UV 254 nm; 1d Densitograms of tracks 1: Enicostemma littorale extract, and 2: SM.	66
3.2	Change in body weight upon induction of diabetes and treatment of diabetic rats with EL, SM and standard drug MFO.	68
3.3a	Effect of EL extract, SM and MFO treatments for 40 days on the post-prandial serum glucose levels in diabetic conditions using GOD-POD.	68
3.3b	Effect of EL extract, SM and MFO treatments for 40 days on the OGTT profile in diabetic conditions using GOD-POD.	68
3.3c	Effect of EL extract, SM and MFO treatments for 40 days on the Serum insulin levels in diabetic conditions using ELISA kit.	68
3.4	Effect of EL extract, SM and MFO treatments for 40 days on the specific activity of G-6-Pase enzyme from hepatic tissue in diabetic conditions.	68
3.5a	Effect of EL extract and SM treatments on the mRNA expression of PEPCK, GK, Glut2 and β-Actin in the hepatic tissue as compared to diabetic rats.	70
3.5b	Effect of EL extract and SM treatments on the expression of PEPCK,GK and Glut2 in the hepatic tissue as compared to diabetic rats using RT-PCR and densitometric analysis.	70
3.6a	Effect of EL extract and SM treatments on the expression of insulin signaling proteins: IR, PI(3)K and β-actin.	70
3.6b	Effect of EL extract and SM treatments on the tyrosine phosphorylation of insulin signaling proteins: IR in the hepatic tissue as compared to diabetic rats.	70
3.7	Effect of EL extract and SM treatments for 40 days on the ratio of (absorbance of HMG-CoA/absorbance of Mevalonate): An index of the of HMG-CoA reductase activity from hepatic tissue in diabetic conditions.	70
3.8a	Effect of EL extract and SM treatments on the mRNA expression of SREBP-	72

	1c, PPAR-γ, Leptin, LPL, Adiponectin, Glut4 and β-actin in the adipose tissue as compared to diabetic rats.	
3.8b	Effect of EL extract and SM treatments on the expression of the major genes regulating the fat metabolism in the adipocytes as compared to diabetic rats.	72
3.8c	Effect of EL extract and SM treatments on the expression of Glut 4 in the adipocytes as compared to diabetic rats using semi-quantitative RT-PCR and densitometric analysis.	72
3.9a	Effect of EL extract and SM treatments on the expression of Insulin signaling proteins: IR, PI(3)K and β-actin.	72
3.9b	Effect of EL extract and SM treatments on the Phosphorylation of Insulin signaling proteins: IR in the adipose tissue tissue as compared to diabetic rats.	72
3.10	Schematic representation of SM in amelioration of insulin resistance and TIIDM.	75
	CHAPTER-4	
4A.1	OA-induced steatosis in HepG2 cells determined by Oil O Red staining , Quantification of Oil O Red stain after extraction procedure; (a) Oil O Red staining observed at 20X magnification under Phase contrast microscope. (b) Quantification of Oil O Red stain after extraction procedure is represented in terms of % of Oil O Red stain compared to control.	92
4A.2	Effect of SM on a) Intracellular triglyceride accumulation. b) % LDH release.	92
4A.3	Effect of SM on Signaling pathways using insulin resistant HepG2: a) Western blot study showing the effect of SM treatments on the expression of PPAR-α, TNF-α and insulin signaling proteins: IR, p_{ser307}-IRS-1, p-Akt and PI(3)K in the HepG2 as compared to OA treated group. β-actin was taken as an internal control. b) Densitometry analysis for the above western profile using image J software.	95
4A.4	Effect of SM on the expression of fat metabolism genes in the liver steatosis. The expression levels of fat metabolic genes PPAR-γ, SREBP-1c, ACC-1, FAS and CPT-1 were checked using quantitative PCR.	96
4B.1	Confirmation of myotubes by indirect immunofluorescence using smooth muscle actin (SMA) taged with FITC and Desmin labeled with CF555 captured.	107
4B.2	Confirmation of myocytes to myotubes differentiation by DMEM with 1% FBS and IGF-1 for 6th days. Western blot study showing Desmin expression in differentiation group and β-actin was taken as an internal control.	108
4B.3	Effect of SM on the expression of skeletal muscle metabolic genes in the TNF-α induced insulin resistant myotubes. The expression levels of metabolic genes GP, G-6-Pase and Glut4 were checked using quantitative PCR.	108
4B.4a	Effect of SM on insulin signaling pathways using insulin resistant L6 myocytubes. Western blot study showing the effect of SM treatments on the expression of Insulin signaling proteins: IR, p_{ser307}-IRS-1, pAkt, PI(3)K	108

	,pP38MAPK,Erk1/2 and Glut4.	
4B.4b	Effect of SM on insulin signaling pathways using insulin resistant L6 myotubes. Densitometric analysis of western blot study showing the effect of SM treatments on the expression of Insulin signaling proteins.	108
4C.1a	Oil O Red staining under 20X magnification under Phase contrast microscope of adipocyte differentiation	122
4C.1b	Quantification of Oil O Red stain after extraction procedure of adipocyte differentiation	122
4C.1c	Cell were lysed for quantification of triglyceride accumulation of adipocyte differentiation	122
4C.1d	Confirmation of mature adipocytes functional genes expression. The expression levels of fat metabolic genes PPAR-γ, CD36, SREBP-1c, Adiponectin, aP2, LPL and β-Actin	122
4C.2	Confirmation of dexamethasone induced insulin resistance model checked for protein content of IR, PI(3)K, PPAR-γ and β-actin.	122
4C.3	The expression levels of fat metabolic genes SREBP-1c, PPAR-γ, LPL CD36, aP2, ACC-1 and Adiponectin	122
4C.4a	Effect of SM treatments on the expression of Insulin signaling proteins: IR-β, p_{ser307} -IRS-1, pAkt, PI(3)K, PPAR-γ and β-actin in the adipocyte as compared to dexamethasone treated group	123
4C.4b	Densitometric analysis: The effect of SM treatments on the expression of Insulin signaling proteins IR-β, p_{ser307} -IRS-1, pAkt, PI(3)K, PPAR-γ and β-actin	123
4C.5a	Effect of SM on the expression of Insulin signaling proteins: IR, p_{ser307} -IRS-1, p-Akt, PI(3)K ,Pp38 MAPK,$Erk_{1/2}$,PKCs, PPAR-γ, Glut4 and β-actin	125
4C.5b	Densitometric analysis: The effect of SM treatments on the expression of Insulin signaling proteins.	125
4C.6	Immunoprecipitation study showing the effect of SM treatments on the tyrosine phosphorylation of insulin signaling proteins	125
4C.7a	Effect of SM treatments on the insulin stimulated glucose uptake assay.	126
4C.7b	Effect of SM treatments on the insulin stimulated glucose uptake assay: Average fluorecence of intensity of cells (arbitrary units).	126
	CHAPTER-5	
5.1	Dose dependent studies of SM in anti-adiopogenic phenotype.	141
5.2	Treatment with adiopogenic cocktail and SM during adipogenesis (a) Gene expressions of C/EBP-β, PPAR-γ2 and GAPDH (b) Densitometric analysis: Gene expression profile of C/EBP-β, PPAR-γ2 and GAPDH in day dependent manner (1-8 Days).	141
5.3	Treatment with adiopogenic cocktail and swertiamarin during adipogenesis PPAR-γ and C/EBP-β protein expressions.	142
5.4a	Treatment with adiopogenic cocktail and SM during adipogenesis: Gene expressions of PPAR-γ2 dependent genes: CD36, aP2, LPL, adiponectin and GAPDH.	142
5.4b	Treatment with SM during adipogenesis and gene expressions of PPAR-γ2 dependent genes profile: CD36 ,aP2, LPL, adiponectin and GAPDH.	142

CHAPTER-6		
6.1a	Effect of PARP Inhibitor(PJ34) on cell viability of preadipocytes, 3T3-L1 cells after 72 hours.	158
6.1b	3T3-L1, preadipocyte treated with DNA Damaging agent (H_2O_2) showed an increase in PARP activity and hence polymer formation. PARP-activation can be abolished by treatment of 10uM of PJ-34 without affecting cell viability. Blot were probed with pADPr (10 H)(1:500) and PARP-1 antibody(1:5000).	158
6.1c	PARP activity (PARylation) was observed during 8 days of adipogenesis in presence and absence of PARP inhibitor PJ-34	160
6.1d	PARP inhibitor, PJ 34 blocked adipogenic phenotype as confirmed by Oil O Red staining. 3T3-L1 preadipocytes were subjected to adipocyte differentiation using adipogenic cocktail for 8 days and were checked by the Oil O Red staining. (i) Oil O Red staining under 20X magnification under Phase contrast microscope (ii) Quantification of Oil O Red stain after extraction procedure is represented in terms of % of Oil O Red stain compared to control	160
6.1e	PJ-34 was treated in early and late phase of adipogenesis, confirmation by (i) Oil O Red staining under 20X magnification under Phase contrast microscope (ii) Quantification of Oil O Red stain after extraction procedure is represented in terms of % of Oil O Red stain compared to control	160
6.2	Anti-adipogenic effect of SM combined with TGF-β ligand (Activin A) with and without PJ-34. 3T3-L1 preadipocytes were subjected to adipocyte differentiation using adipogenic cocktail for 8 days and were checked by the Oil O Red staining. ;(a) Oil O Red staining under 20X magnification under Phase contrast microscope (b) Quantification of Oil O Red stain after extraction procedure is represented in terms of % of Oil O Red stain compared to control	161
6.3a	PARP activity and it's expression when treated with Activin A in presence & absence of PJ-34 in Early and Late phase of Adipogenesis. Blot were probed with pADPr (10 H) (1: 500) and PARP-1 antibody(1:5000)	162
6.3b	PARP activity and it's expression when treated with Activin A in presence & absence of PJ-34 in Early and Late phase of Adipogenesis. Blot were probed with pADPr (10 H) (1: 500) and PARP-1 antibody(1:5000).	162
6.3c	After treatment with PJ-34 SM, Activin-A and their combinations, PARylation was observed by probing the blot with 10H antibody.	162
6.4	After treatment with Activin-A, PJ-34 and their combinations during adipogenesis (a) Gene expressions of PPARγ-2, CD36, aP2 and adiponectin were checked using semi-quantitative RT-PCR. (b) PPAR-γ and C/EBP-β protein expressions were checked by western blotting.	163
6.5a	siRNA mediated down regulation of PARP-1: Western blotting and Oil O Red staining	165
6.5b	PARP-1: Gene expression of Adipogenic transcription factors: PPARγ2, Adiponectin and Leptin:	165
6.6a	Expression of pSmad3 with PAR by Immunocytochemistry on 2nd and 5th day of adipogenesis	166

6.6b	Protein expression of pSmad3 and PARP-1 in chromatin fraction during adipogenesis.	167
6.6c	Co-Immunoprecipitation study showing the interaction of pSmad3 with PARP-1.	167
6.7	ChIP study: Interaction of pSmad3 with C/EBPs and PPARγ promoters	168